| [1] | Eisenbarth G (1986) Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360–1368.
|
| [2] | Bluestone JA, Tang Q (2004) Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proceedings of the National Academy of Sciences of the United States of America 101: 14622–14626.
|
| [3] | Viglietta V, Kent SC, Orban T, Hafler DA (2002) GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. The Journal of Clinical Investigation 109: 895–903.
|
| [4] | Danke NA, Yang J, Greenbaum C, Kwok WW (2005) Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. Journal of Autoimmunity 25: 303–311.
|
| [5] | Zhao C, Davies JD (2010) A peripheral CD4+ T cell precursor for naive, memory, and regulatory T cells. The Journal of Experimental Medicine 207: 2883–2894.
|
| [6] | Flynn J, McInerney M (2000) High density insulin receptor-positive diabetogenic T lymphocytes in nonobese diabetic mice are memory cells. Immunopharmacol Immunotoxicol 22: 387–400.
|
| [7] | ？ling V, Reijonen H, Simell O, Knip M, Ilonen J (2012) Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes. Cellular Immunology 273: 133–139.
|
| [8] | Li C-R, Baaten BJG, Bradley LM (2012) Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes. Journal of Molecular Cell Biology 4: 38–47.
|
| [9] | Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531–562.
|
| [10] | Lobell A, Weissert R, Eltayeb S, de Graaf KL, Wefer J, et al. (2003) Suppressive DNA Vaccination in Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis Involves a T1-Biased Immune Response. The Journal of Immunology 170: 1806–1813.
|
| [11] | Fontenot J, Gavin M, Rudensky A (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330–336.
|
| [12] | Shevach E (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2: 389–400.
|
| [13] | Ferrera F, La Cava A, Rizzi M, Hahn B, Indiveri F, et al. (2007) Gene vaccination for the induction of immune tolerance. Ann N Y Acad Sci 1110: 99–111.
|
| [14] | Battaglia M, Roncarolo M-G (2011) Immune intervention with T regulatory cells: Past lessons and future perspectives for type 1 diabetes. Seminars in Immunology 23: 182–194.
|
| [15] | Wang B, Tisch R (2008) Parameters influencing antigen-specific immunotherapy for type 1 diabetes. Immunologic Research 41: 175–187.
|
| [16] | Hutchings P, Cooke A (1998) Protection from Insulin Dependent Diabetes Mellitus Afforded by Insulin Antigens in Incomplete Freund’s Adjuvant Depends on Route of Administration. Journal of Autoimmunity 11: 127–130.
|
| [17] | Zhang W, Jin H, Hu Y, Yu Y, Li X, et al. (2010) Protective Response Against Type 1 Diabetes in Nonobese Diabetic Mice After Coimmunization with Insulin and DNA Encoding Proinsulin Human Gene Therapy. 21: 171–178.
|
| [18] | Kang Y, Xu L, Wang B, Chen A, Zheng G (2008) Cutting Edge: Immunosuppressant as Adjuvant for Tolerogenic Immunization. The Journal of Immunology 180: 5172–5176.
|
| [19] | Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, et al. (2007) Dendritic cells with TGF-β1 differentiate na？ve CD4+CD25？ T cells into islet-protective Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences 104: 2821–2826.
|
| [20] | Wong J, Mathis D, Benoist C (2007) TCR-based lineage tracing: no evidence for conversion of conventional into regulatory T cells in response to a natural self-antigen in pancreatic islets. The Journal of Experimental Medicine 204: 2039–2045.
|
| [21] | Lo J, Peng R, Barker T, Xia C, Clare-Salzler M (2006) Peptide-pulsed immature dendritic cells reduce response to beta cell target antigens and protect NOD recipients from type I diabetes. Ann N Y Acad Sci 1079: 153–156.
|
| [22] | Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, et al. (1999) Glucocorticoids Affect Human Dendritic Cell Differentiation and Maturation. The Journal of Immunology 162: 6473–6481.
|
| [23] | Dai Y, Carayanniotis G, Sercarz E (2005) Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2: 169–175.
|
| [24] | Gepts W, Lecompte P (1981) The pancreatic islets in diabetes. Am J Med 70: 105–115.
|
| [25] | Budd RC, Cerottini JC, Horvath C, Bron C, Pedrazzini T, et al. (1987) Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. The Journal of Immunology 138: 3120–3129.
|
| [26] | Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, et al. (2001) A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. The Journal of Clinical Investigation 107: 173–180.
|
| [27] | Kelemen K, Gottlieb PA, Putnam AL, Davidson HW, Wegmann DR, et al. (2004) HLA-DQ8-Associated T Cell Responses to the Diabetes Autoantigen Phogrin (IA-2β) in Human Prediabetes. The Journal of Immunology 172: 3955–3962.
|
| [28] | Godebu E, Summers-Torres D, Lin MM, Baaten BJG, Bradley LM (2008) Polyclonal Adaptive Regulatory CD4 Cells That Can Reverse Type I Diabetes Become Oligoclonal Long-Term Protective Memory Cells. The Journal of Immunology 181: 1798–1805.
|
| [29] | Monti P, Scirpoli M, Rigamonti A, Mayr A, Jaeger A, et al. (2007) Evidence for In Vivo Primed and Expanded Autoreactive T Cells as a Specific Feature of Patients with Type 1 Diabetes. The Journal of Immunology 179: 5785–5792.
|
| [30] | Weber SE, Harbertson J, Godebu E, Mros GA, Padrick RC, et al. (2006) Adaptive Islet-Specific Regulatory CD4 T Cells Control Autoimmune Diabetes and Mediate the Disappearance of Pathogenic Th1 Cells In Vivo. The Journal of Immunology 176: 4730–4739.
|
| [31] | Monfar M, Blenis J (1996) Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone. Molecular Endocrinology 10: 1107–1115.
|
| [32] | Franchimont D (2004) Overview of the Actions of Glucocorticoids on the Immune Response: A Good Model to Characterize New Pathways of Immunosuppression for New Treatment Strategies. Annals of the New York Academy of Sciences 1024: 124–137.
|
| [33] | Chen X, Murakami T, Oppenheim JJ, Howard OMZ (2004) Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone-induced cell death. European Journal of Immunology 34: 859–869.
|
| [34] | Yagi H, Matsumoto M, Kunimoto K, Kawaguchi J, Makino S, et al. (1992) Analysis of the roles of CD4+ and CD8+ T cells in autoimmune diabetes of NOD mice using transfer to NOD athymic nude mice. Eur J Immunol 22: 2387–2393.
|
| [35] | Wong FS, Visintin I, Wen L, Flavell RA, Janeway CA (1996) CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells. The Journal of Experimental Medicine 183: 67–76.
|
| [36] | Tang Q, Bluestone JA (2006) Regulatory T-cell physiology and application to treat autoimmunity. Immunological Reviews 212: 217–237.
|
| [37] | Li C-R, Deiro MF, Godebu E, Bradley LM (2011) IL-7 uniquely maintains FoxP3+ adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization. Journal of Autoimmunity 37: 217–227.
|
| [38] | Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M (2005) A peripheral circulating compartment of natural naive CD4+ Tregs. The Journal of Clinical Investigation 115: 1953–1962.
|
| [39] | Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, et al. (2006) Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 108: 3371–3378.
|
| [40] | Atkinson MA, Maclaren NK, Luchetta R (1990) Insulitis and Diabetes in NOD Mice Reduced by Prophylactic Insulin Therapy. Diabetes 39: 933–937.
|
| [41] | Kang Y, Zhao J, Liu Y, Chen A, Zheng G, et al. (2009) FK506 as an adjuvant of tolerogenic DNA vaccination for the prevention of experimental autoimmune encephalomyelitis. The Journal of Gene Medicine 11: 1064–1070.
|
